Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

Multiparametric analyses of phospho-protein activation in patients with acute myeloid leukemia (AML) offers a quantitative measure to monitor the activity of novel intracellular kinase (IK) inhibitors. As recent clinical investigation with FMS-like tyrosine-3 inhibitors demonstrated, targeting IK with selective inhibitors can have a modest clinical benefit. Because multiple IKs are active in patients with AML, multikinase inhibitors may provide the necessary inhibition profile to achieve a more sustained clinical benefit. We here describe a method of assessing the activation of several IKs by flow cytometry. In 40 different samples of patients with AML we observed hyper-activated phospho-proteins at baseline, which is modestly increased by adding stem cell factor to AML cells. Finally, AML cells had a significantly different phospho-protein profile compared with cells of the lymphocyte gate. In conclusion, our method offers a way to determine the activation status of multiple kinases in AML and hence is a reliable assay to evaluate the pharmacodynamic activity of novel multikinase inhibitors.

[1]  S. Akinaga,et al.  A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. , 2009, Blood.

[2]  F. Craig,et al.  Flow cytometric immunophenotyping for hematologic neoplasms. , 2008, Blood.

[3]  C. Paige,et al.  Heparan Sulfate and Heparin Enhance ERK Phosphorylation and Mediate preBCR-Dependent Events during B Lymphopoiesis1 , 2008, The Journal of Immunology.

[4]  K. Tanriverdi,et al.  Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. , 2007, Leukemia research.

[5]  Nick Holford,et al.  Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. , 2006, Blood.

[6]  M. Minden,et al.  Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. , 2006, Experimental hematology.

[7]  R. Paulson,et al.  Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. , 2006, Gene.

[8]  D. Hedley,et al.  Pharmacodynamic monitoring of BAY 43‐9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells , 2006, Cytometry. Part B, Clinical cytometry.

[9]  O. Perez,et al.  Phospho‐proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single‐cell level , 2006, Immunological reviews.

[10]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[11]  M. Harnett,et al.  Differences in the Kinetics, Amplitude, and Localization of ERK Activation in Anergy and Priming Revealed at the Level of Individual Primary T Cells by Laser Scanning Cytometry1 , 2004, The Journal of Immunology.

[12]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[13]  A. Stopeck,et al.  Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. , 2004, Leukemia research.

[14]  J. Harbott,et al.  High Expression Levels of X-Linked Inhibitor of Apoptosis Protein and Survivin Correlate with Poor Overall Survival in Childhood de Novo Acute Myeloid Leukemia , 2004, Clinical Cancer Research.

[15]  M. Heinrich,et al.  An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[17]  Peter O. Krutzik,et al.  Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[19]  Adolfas K. Gaigalas,et al.  Quantitating Fluorescence Intensity From Fluorophores: Practical Use of MESF Values , 2002, Journal of research of the National Institute of Standards and Technology.

[20]  Donna Neuberg,et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.

[21]  D. Small,et al.  Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor , 2001, Leukemia.

[22]  F. Sigaux,et al.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia , 2000, British journal of haematology.

[23]  M. Borowitz,et al.  Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. , 1993, American journal of clinical pathology.

[24]  Gordon B Mills,et al.  Functional proteomic profiling of AML predicts response and survival. , 2009, Blood.

[25]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[26]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[27]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.